Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 1/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.33 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | HTR2A | P28223 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL286513 | 0.81 | CYP4F2 (0.33) | HTR2A | |
| SCHEMBL23536611 | 0.80 | IMPDH2 (0.33) | AGTR1ALDH1A1SMN1; SMN2HTR2A | |
| SCHEMBL30014250 | 0.80 | GABRA1 (0.34) | GABRA1GABRB2PKMHTR2A | |
| SCHEMBL10717222 | 0.80 | GABRA1 (0.34) | GABRA1GABRB2PKMHTR2A | |
| SCHEMBL8357239 | 0.78 | AGTR1 (0.36) | AGTR1ALDH1A1SMN1; SMN2 | |
| SCHEMBL18133370 | 0.77 | RIPK1 (0.37) | ALDH1A1SMN1; SMN2PKM | |
| SCHEMBL11138242 | 0.77 | HTT (0.38) | GABRA1GABRB2ALDH1A1 | |
| SCHEMBL19507340 | 0.77 | GABRA1 (0.50) | GABRA1GABRB2 | |
| SCHEMBL20614207 | 0.74 | ALDH1A1 (0.35) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL15715518 | 0.74 | HTR2A (0.48) | ALDH1A1SMN1; SMN2HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230271973-A1 | BICYCLIC-HETEROCYCLE DERIVATIVES AND THEIR USES AS OREXIN-2 RECEPTOR AGONISTS | CENTESSA PHARMACEUTICALS (OREXIA) LIMITED (GB) | 2023-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230271973-A1 | BICYCLIC-HETEROCYCLE DERIVATIVES AND THEIR USES AS OREXIN-2 RECEPTOR AGONISTS | HCRTR2, HCRTR1, CRHR2 | AGTR1 320/4885GABRA1 123/4885GABRB2 109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.